Meeting
2017 ASCO Annual Meeting
Phase Ib study of cetuximab + BYL719 + IMRT in stage III-IVB head and neck squamous cell carcinoma (HNSCC).
Authors
Lara Dunn
Memorial Sloan Kettering Cancer Center, New York, NY
Lara Dunn , Nadeem Riaz , Shrujal S. Baxi , Sean Matthew McBride , Eric Jeffrey Sherman , Loren Michel , Sofia Haque , Nora Katabi , Richard J. Wong , Han Xiao , Nancy Y. Lee , Matthew G. Fury , Alan Loh Ho , David G. Pfister
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Local-Regional Disease
Clinical Trial Registration Number
NCT02282371
Citation
J Clin Oncol 35, 2017 (suppl; abstr 6081)
DOI
10.1200/JCO.2017.35.15_suppl.6081
Abstract #
6081
Poster Bd #
69
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Phase I trial of cetuximab, intensity modulated radiotherapy (IMRT), and the anti-CTLA-4 monoclonal antibody (mAb) ipilimumab in previously untreated, locally advanced head and neck squamous cell carcinoma (PULA HNSCC).
First Author: Julie E. Bauman
Poster
2023 ASCO Annual Meeting
Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable high grade glioma patients: OLA-TMZ-RTE-01.
First Author: Dinu Stefan
Poster
2022 ASCO Annual Meeting
A phase 1/2 trial to evaluate the safety and antitumor activity of tipifarnib and alpelisib for patients with PIK3CA-mutated/amplified and/or HRAS-overexpressing recurrent/metastatic head and neck squamous cell carcinoma.
First Author: Glenn J. Hanna
Poster
2021 ASCO Annual Meeting
Phase I study of functionalized hafnium oxide nanoparticles (NBTXR3) activated by radiotherapy in cisplatin-ineligible locally advanced HNSCC patients.
First Author: Christophe Le Tourneau